Puma triples on neratinib adjuvant breast cancer data
This article was originally published in Scrip
Executive Summary
Puma Biotechnology's stock tripled in after-hours trading on 22 July after the company said it would seek regulatory approval based on Phase III results for its tyrosine kinase inhibitor neratinib in a Phase III clinical trial for the extended adjuvant treatment of breast cancer.